LivaNova PLC (LIVN) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-01, LivaNova PLC (NASDAQ: LIVN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $81.25 (+0.73% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #179 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($173.3M FCF) & 67.7% Gross Margin
Altman Z-Score 2.21 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 7/9
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
Even with a 61/100 (C-) score, LIVN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($78.49) or 200D SMA ($72.90) invalidates the momentum regime and cuts Target Base ($82.35) toward Bear Floor ($64.23).
LivaNova PLC (LIVN) advanced +0.73% to $81.25, trading at 88% of its 52-week range ($48.82 – $85.76). Solid 68% profit margin (17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of +25.00% and -3.40%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
GLOUCESTER, England, October 23, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS
GLOUCESTER, England, October 21, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that members of the Company’s Executive Leadership Team will provide general business updat
LivaNova offers affordable growth: solid EPS/revenue growth, moderate valuation, strong profitability, but weaker health and ROIC warrant caution.
By Karen Roman Slate Medicines, Inc. said Stephen K. Brannan, MD, and John D. Young were appointed to the company’s Board of Directors. Dr. Brannan has over 25 years of clinical development experience in central nervous
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LIVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LIVN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, LivaNova PLC (LIVN) ranks #179 by composite RQD confidence (61/100, grade C-) and #171 by equity capitalization ($4.48B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. TMDX currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with LIVN at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LIVN
ACTIVE
LivaNova PLC | C- | 61/100 | — | 67.7% | 17.3% | +0.73% | $4.48B | Benchmark Subject |
| ITGR Integer Holdings Corporation | C+ | 67/100 | 41.8x | 27.0% | 6.0% | -0.02% | $4.30B | /itgr-vs-livn → |
| AXGN Axogen Inc. | D+ | 54/100 | — | 74.3% | -2.6% | +0.77% | $2.96B | /axgn-vs-livn → |
| TMDX TransMedics Group Inc. | C+ | 69/100 | 12.2x | 59.9% | 18.1% | +0.33% | $2.33B | /tmdx-vs-livn → |
| CNMD CONMED Corporation | C | 62/100 | 28.9x | 54.6% | 7.8% | -0.09% | $1.36B | /cnmd-vs-livn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), LivaNova PLC (LIVN) reported GAAP revenue of $1.39B (+10.7% vs. FY2024 revenue of $1.25B , and +20.3% cumulative change since FY2023) , GAAP net income of -$242.5M, operating cash flow of $254.3M, and free cash flow of $173.3M (+27.5% YoY). On the balance sheet, LIVN closed FY2025 with $2.61B in total assets against $345.2M in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.39B | -$242.5M | $254.3M | $173.3M | $2.61B | $345.2M |
| FY2024 (FY) | 2024-12-31 | $1.25B | $63.2M | $183.0M | $135.9M | $2.51B | $549.6M |
| FY2023 (FY) | 2023-12-31 | $1.15B | $17.6M | $74.9M | $74.9M | — | — |
As of 2026-11-01, LivaNova PLC (NASDAQ: LIVN) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $81.25 (+0.73% 1D, market cap $4.48B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, LIVN ranks #179 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
LIVN last traded at $81.25 (+0.73% on volume of 483,339 shares), positioning the stock +3.52% above its 50-day simple moving average ($78.49) and +11.45% above its 200-day simple moving average ($72.90). Across its 52-week range of $48.82 to $85.76, LIVN sits at the 87.8% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($76.29 to $86.21).
Why LIVN Stock advanced +0.73% Today — RQD Quant Desk Flash. Solid 68% profit margin (17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.